1,700 Shares in Insulet Co. (NASDAQ:PODD) Purchased by Katamaran Capital LLP

Katamaran Capital LLP purchased a new stake in shares of Insulet Co. (NASDAQ:PODD) in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 1,700 shares of the medical instruments supplier’s stock, valued at approximately $444,000. Insulet accounts for 0.6% of Katamaran Capital LLP’s holdings, making the stock its 28th biggest position.

Other large investors have also added to or reduced their stakes in the company. Baillie Gifford & Co. grew its position in shares of Insulet by 3.5% during the 4th quarter. Baillie Gifford & Co. now owns 2,355,683 shares of the medical instruments supplier’s stock valued at $614,998,000 after acquiring an additional 79,982 shares during the period. Geode Capital Management LLC grew its holdings in Insulet by 2.3% during the fourth quarter. Geode Capital Management LLC now owns 1,779,167 shares of the medical instruments supplier’s stock valued at $463,347,000 after purchasing an additional 40,566 shares during the period. Norges Bank purchased a new stake in Insulet in the fourth quarter worth $248,806,000. Artisan Partners Limited Partnership raised its stake in shares of Insulet by 24.1% in the fourth quarter. Artisan Partners Limited Partnership now owns 770,188 shares of the medical instruments supplier’s stock valued at $201,073,000 after buying an additional 149,524 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its position in shares of Insulet by 1.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 646,959 shares of the medical instruments supplier’s stock valued at $168,902,000 after buying an additional 10,694 shares during the last quarter.

Insider Activity at Insulet

In related news, Director Wayne A.I. Frederick sold 1,825 shares of the company’s stock in a transaction on Tuesday, March 25th. The stock was sold at an average price of $275.00, for a total value of $501,875.00. Following the sale, the director now directly owns 3,231 shares of the company’s stock, valued at $888,525. This represents a 36.10 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Eric Benjamin sold 12,394 shares of the firm’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total value of $3,470,320.00. Following the transaction, the executive vice president now directly owns 11,383 shares of the company’s stock, valued at $3,187,240. This represents a 52.13 % decrease in their position. The disclosure for this sale can be found here. 0.47% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on PODD shares. TD Cowen boosted their price objective on Insulet from $264.00 to $324.00 and gave the company a “buy” rating in a research note on Friday, January 3rd. Stifel Nicolaus boosted their price target on shares of Insulet from $245.00 to $293.00 and gave the company a “hold” rating in a research report on Friday, February 21st. Raymond James reaffirmed an “outperform” rating and issued a $328.00 price objective (up from $294.00) on shares of Insulet in a report on Friday, February 21st. JPMorgan Chase & Co. boosted their target price on shares of Insulet from $280.00 to $330.00 and gave the company an “overweight” rating in a report on Thursday, December 12th. Finally, StockNews.com lowered Insulet from a “buy” rating to a “hold” rating in a report on Tuesday, March 4th. Four research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $292.06.

Insulet Price Performance

PODD opened at $245.26 on Friday. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. The stock has a market capitalization of $17.22 billion, a P/E ratio of 42.36, a PEG ratio of 3.62 and a beta of 1.30. The stock has a 50-day moving average price of $269.86 and a 200-day moving average price of $259.53. Insulet Co. has a 12-month low of $160.19 and a 12-month high of $289.46.

Insulet (NASDAQ:PODD) last issued its earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $1.00 by $0.15. Insulet had a net margin of 20.19% and a return on equity of 24.46%. The company had revenue of $597.50 million for the quarter, compared to analysts’ expectations of $582.02 million. Equities analysts predict that Insulet Co. will post 3.92 earnings per share for the current fiscal year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.